Sang il Kim, PhD

Principal Scientist

Sang il has worked on antibody discovery and antibody engineering
projects for more than 8 years. Prior to joining Centivax, he has
discovered several potent anti-SARS-CoV-2, MERS-CoV, and ZIKV neutralizing
antibodies from patients. He has identified stereotypic neutralizing
antibodies against SARS-CoV-2 RBD in healthy individuals and COVID-19
patients (Sci Transl Med, 2020). He also generated nebulizable
MERS-CoV neutralizing antibody for delivery via a pulmonary route. He
received a PhD in cancer biology from Seoul National University
College of Medicine and a B.S. in biochemistry from the University of
California, San Diego.